|
Evaluating a novel oncologist-led BRCA1/2 mutation (BRCAm) testing counseling model for patients with ovarian cancer: Interim results from the ENGAGE study. |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Other Relationship - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca |
Speakers' Bureau - AstraZeneca |
Research Funding - AstraZeneca |
|
|
No Relationships to Disclose |
|
Jose Antonio Lopez-Guerrero |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Roche |
Travel, Accommodations, Expenses - PharmaMar |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AAIPharma |
|
|
|
|
|
|
Stock and Other Ownership Interests - AAIPharma |
|
|
No Relationships to Disclose |